Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Lymphoma Clinical Trial

Official title:

Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00392834
• Other study ID #: AMC-048
• Secondary ID: U01CA070019CDR00
• Status: Completed
• Phase: Phase 2
• Start date: September 2006
• Est. completion date: July 2013

Study information

• Verified date: May 2018
• Source: AIDS Malignancy Consortium
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with newly diagnosed, HIV-associated Burkitt's lymphoma.

Description:

OBJECTIVES:

Primary

• Determine the efficacy of rituximab, cyclophosphamide, vincristine, doxorubicin hydrochloride, and high-dose methotrexate (R-CODOX-M ) alone or alternating with rituximab and ifosfamide, etoposide phosphate, and high-dose cytarabine (IVAC) and intrathecal CNS prophylaxis in patients with newly diagnosed, previously untreated, HIV-associated Burkitt's lymphoma or atypical Burkitt's lymphoma.

• Determine the safety of this regimen in these patients.

Secondary

• Evaluate downstream effectors of apoptosis as mechanisms of chemotherapy resistance and prognosis and perform exploratory analysis of their relationship to treatment effect.

• Evaluate multi-drug resistance gene expression as a mechanism of chemotherapy resistance and prognosis and perform exploratory analysis of their relationship to treatment effect.

• Confirm the use of flow cytometry in the identification of occult leptomeningeal disease and determine whether abnormal flow cytometry is predictive when CNS cytology is negative for malignant cells.

• Determine the biologic and prognostic significance of Epstein-Barr virus (EBV)-positive Burkitt's lymphoma in the highly active antiretroviral therapy era and perform exploratory analysis of their relationship to treatment effect.

• Compare genotyping in patients with HIV-associated Burkitt's lymphoma with that of patients who are HIV-negative and determine whether they are uniform in their genetic profile or whether some cases are more like diffuse large B-cell lymphoma.

• Determine if EBV detection in cerebrospinal fluid at diagnosis is predictive of leptomeningeal disease.

OUTLINE: This is a prospective, multicenter study. Patients are stratified according to risk category (low-risk vs high-risk). Patients with low-risk disease receive 3 courses of R-CODOX-M chemotherapy as described below. Patients with high-risk disease receive 4 alternating courses of R-CODOX-M/IVAC chemotherapy as described below in an A/B/A/B sequence.* Courses repeat every 21-28 days in the absence of disease progression or unacceptable toxicity.

NOTE: *In patients presenting with anasarca, pleural effusion, or ascites, methotrexate can pool causing difficulties with clearance; in this case, treatment may be given in a reverse sequence: B/A/B/A.

• Regimen A (R-CODOX-M chemotherapy): Patients receive rituximab** IV and doxorubicin hydrochloride IV over 15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on days 1 and 2, pegfilgrastim subcutaneously (SC) on day 3, vincristine IV on days 1 and 8, high-dose methotrexate IV over 2-4 hours on day 15, and leucovorin calcium IV beginning 24 hours after the start of methotrexate and continuing every 6 hours until the methotrexate level is less than 50 nmol/L. Patients receive CNS prophylaxis comprising methotrexate intrathecally (IT), cytarabine IT, and hydrocortisone IT on day

1. Patients with high-risk disease receive an additional dose of cytarabine IT on day 3. Patients also receive filgrastim (G-CSF) SC once daily on days 3-9. Once the methotrexate levels drops below 50 nmol/L, patients resume G-CSF SC once daily beginning on approximately day 18 and continuing until blood counts recover.

• Regimen B (rituximab and IVAC chemotherapy): Patients receive rituximab** IV on day 1, ifosfamide IV continuously and etoposide IV continuously over 24 hours on days 1-5, and high-dose cytarabine IV over 1-3 hours twice daily on days 1-2. Patients receive CNS prophylaxis comprising methotrexate IT and hydrocortisone IT on day 5. Patients also receive pegfilgrastim SC once 24-48 hours after completion of chemotherapy OR G-CSF SC beginning on day 6 and continuing until blood counts recover.

Patients with CNS involvement (leptomeningeal and/or intraparenchymal) at diagnosis do not receive CNS prophylaxis as above. Instead, these patients receive a combination of sequential liposomal cytarabine and methotrexate IT or via an Ommaya reservoir on day 1 and then every 14 days as tolerated until completion of systemic chemotherapy.

NOTE: **Rituximab may be given up to 3 days before a chemotherapy course and anytime during the course for 3 (low-risk disease) or 4 (high-risk disease) total doses.

Patients undergo blood and cerebrospinal fluid collection and tumor biopsies periodically during study treatment for correlative studies of prognostic biomarkers predictive of survival (e.g., c-flip protein expression; p53 mutations [by immunohistochemistry (IHC)]; multidrug resistance gene expression [by IHC]; and Epstein-Barr virus in tumor DNA or cerebrospinal fluid [by polymerase chain reaction]); genotyping of Burkitt's lymphoma; and flow cytometry as a tool (by staining) for detecting occult positivity of leptomeningeal disease in Burkitt's lymphoma.

After completion of study treatment, patients are followed every 4 months for at least 2 years.

PROJECTED ACCRUAL: A total of 34 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: July 2013
• Est. primary completion date: July 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and BL)

• Any stage disease

• Newly diagnosed disease

• Meets 1 of the following criteria for disease risk:

• Low-risk disease, defined by 1 of the following:

• Stage I with a single focus of disease < 10 cm AND normal lactate dehydrogenase (LDH) level

• Totally resected intra-abdominal disease only AND normal LDH post surgery

• High-risk disease, defined as not meeting criteria for low-risk disease

• Measurable or nonmeasurable disease

• HIV-positive confirmed by enzyme-linked immunosorbent assay and Western blot OR by measurable HIV viral load

• No visceral Kaposi's sarcoma

PATIENT CHARACTERISTICS:

• Karnofsky performance status 40-100%

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• LVEF = 50% by MUGA or echocardiogram

• Creatinine = 1.5 mg/dL OR creatinine clearance = 60 mL/min

• Absolute neutrophil count = 1,000/mm³

• Platelet count = 50,000/mm³ (unless related to lymphoma)*

• Direct bilirubin = 2.0 mg/dL OR total bilirubin = 3.5 mg/dL AND direct bilirubin normal (if elevated bilirubin secondary to antiretroviral therapy)

• AST and ALT = 3 times upper limit of normal

• No other malignancy within the past 5 years except curatively treated cutaneous basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or cutaneous Kaposi's sarcoma

• No other medical illness unrelated to non-Hodgkin's lymphoma, including any of the following:

• Uncontrolled infection (including opportunistic infection)

• Chronic renal insufficiency

• Myocardial infarction within the past 6 months

• Unstable angina

• Cardiac arrhythmias other than chronic atrial fibrillation

• Patients with active hepatitis B infection are eligible provided they receive concurrent dual antiviral therapy NOTE: *Patients with bone marrow involvement are eligible irrespective of blood count

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior therapy for this disease except for 1 of the following :

• Seven consecutive days of steroids alone or in combination with a non-CHOP regimen necessary for patient stabilization (e.g., cyclophosphamide and steroids steroids for normalization of disease-related hyperbilirubinemia)

• One course of CHOP or fractionated CHOP (e.g. CODOX) with or without rituximab

• No epoetin alfa or filgrastim (G-CSF) within 24 hours of study chemotherapy

• No concurrent zidovudine

Related Conditions & MeSH terms

• Burkitt Lymphoma
• Lymphoma

Intervention

Biological:
• filgrastim
given subcutaneously
• pegfilgrastim
given subcutaneously
• rituximab
given IV

Drug:
• cyclophosphamide
given IV
• cytarabine
given intrathecally
• doxorubicin hydrochloride
given IV
• etoposide
given IV
• ifosfamide
given IV
• leucovorin calcium
given IV
• liposomal cytarabine
given intrathecally
• methotrexate
given intrathecally
• therapeutic hydrocortisone
given intrathecally
• vincristine sulfate
given IV

Locations

Country	Name	City	State
United States	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Baltimore	Maryland
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Albert Einstein Cancer Center at Albert Einstein College of Medicine	Bronx	New York
United States	West Virginia University Health Sciences Center - Charleston	Charleston	West Virginia
United States	Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center	Columbus	Ohio
United States	Rebecca and John Moores UCSD Cancer Center	La Jolla	California
United States	UCLA Clinical AIDS Research and Education (CARE) Center	Los Angeles	California
United States	USC/Norris Comprehensive Cancer Center and Hospital	Los Angeles	California
United States	Memorial Sloan-Kettering Cancer Center	New York	New York
United States	Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia	Philadelphia	Pennsylvania
United States	Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis	Saint Louis	Missouri
United States	UCSF Medical Center at Parnassus	San Francisco	California
United States	Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center	Seattle	Washington

Sponsors (3)

Lead Sponsor	Collaborator
AIDS Malignancy Consortium	National Cancer Institute (NCI), The EMMES Corporation

Country where clinical trial is conducted

United States, 

References & Publications (1)

Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L; AIDS Malignancy Consortium. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015 Jul 9;126(2):160- — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival (OS) at 1 Year		1 year post treatment
Secondary	Complete Response Rate		6-8 weeks post treatment, every 4 months post-treatment for 2 years
Secondary	Failure-free Survival (FFS)		6-8 weeks post treatment, every 4 months post-treatment for 2 years
Secondary	Event-free Survival (EFS)		6-8 weeks post treatment, every 4 months post-treatment for 2 years
Secondary	Toxicity		baseline through 2 years post-treatment
Secondary	Incidence of Infection-related Deaths		baseline through 2 years post-treatment
Secondary	Correlation of C-flip Expression, p53 Mutations, and Multidrug Resistance Expression With OS, FFS, and EFS		baseline through 2 years post-treatment
Secondary	Utility of Flow Cytometry in Detecting Leptomeningeal Disease		baseline and 6-8 weeks post-treatment
Secondary	Degree of Disconcordance Between Flow Cytometry and CNS Cytology Results		baseline
Secondary	Biologic and Prognostic Significance of Epstein-Barr Virus (EBV) at Diagnosis and Correlation With OS, FFS, and EFS		baseline through 2 years post-treatment
Secondary	Correlation of EBV Load Measurements With OS, FFS, and EFS		baseline through 2 years post-treatment